Seagen Plots New Biologics Plant to Amp Up Antibody Drug Production


Seagen announced it is building a 270,000-square-foot facility in Everett, Washington to bolster its drug manufacturing capabilities. Slated to open in 2024 just north of the company’s existing headquarters, the biologics facility plans to employ up to 200 workers.

“In cancer research and development, Seagen must continue to be agile and flexible, especially in manufacturing, to advance our promising pipeline of medicines for people living with cancer and bring these medicines to patients as fast as possible,” said Clay Siegall, Ph.D, CEO of Seagen.